Generic metronidazole is the name used for FDA-approved products containing metronidazole as their active ingredient, but the word generic does not identify a single interchangeable package. In the U.S. oral market, 250 mg and 500 mg immediate-release tablets, 375 mg capsules and other formulation-specific products must be distinguished before evaluating a prescription. The right comparison is between products of the same route, dosage form and strength with appropriate approval and therapeutic-equivalence information, not merely the same ingredient name.
The historical Flagyl name adds another layer. FDA records place branded FLAGYL 250 mg and 500 mg tablets on the discontinued drug product list, while FDA-approved generic metronidazole tablets are a separate regulatory and dispensing question. Discontinued marketing of a reference brand is not proof that its approved generic versions are prohibited, but neither is an Orange Book entry proof that a particular pharmacy has stock. Read the Flagyl brand-status guide alongside this page rather than assuming all Flagyl presentations have the same history.
This guide is designed for readers checking a proposed generic substitution or pharmacy label after a clinician has established a need for oral treatment. It explains what FDA approval and equivalence mean, where formulation boundaries lie and which details to confirm before dispensing. Readers who first need to understand the broader oral product selection can start with the oral metronidazole hub.
A U.S. generic drug is approved through a regulatory pathway that requires an appropriate relationship to a reference product, with relevant standards for active ingredient, dosage form, strength, route and bioequivalence. A generic may differ in certain inactive ingredients, appearance or packaging. These differences do not automatically invalidate approval, but patients with relevant sensitivities should discuss them with a pharmacist.
A common error is interpreting an FDA-approved generic tablet as an approved generic of every product containing the same molecule. Metronidazole is also formulated as vaginal gel and dermal cream, among others. Those products have different routes and labels; the generic status of an oral tablet says nothing about a topical or vaginal substitution.
| Listing you see | What it can identify | What it does not establish |
|---|---|---|
| Metronidazole 250 mg tablet | Oral tablet strength and dosage form | That the order calls for 500 mg, capsule or gel |
| Metronidazole 500 mg tablet | A separate oral tablet strength | A valid change in prescribed tablet quantity |
| Metronidazole 375 mg capsule | Capsule form with a distinct strength | Equivalence to a 250 mg or 500 mg tablet order |
| Metronidazole ER 750 mg | Extended-release oral formulation | Immediate-release interchangeability |
| Generic 0.75% vaginal gel | Intravaginal formulation | Equivalence to topical rosacea gel |
The FDA Orange Book lists approved drug products and therapeutic-equivalence information in defined dosage form, strength and route categories. Search by active ingredient or trade name, then inspect the product's particular row rather than treating metronidazole as one undifferentiated class. Orange Book status and labeling should be interpreted together for a meaningful product comparison.
A therapeutically equivalent generic can be a legitimate dispensing choice under applicable state substitution rules and the prescription's terms. A pharmacist still must confirm that the actual dispensed product is appropriate and authorized. Approval status, marketing status and stock are separate questions, so a listing in the Orange Book cannot replace a current call to the dispensing pharmacy.
In September 2024 the FDA explained that the branded 250 mg and 500 mg FLAGYL tablet products remained in the discontinued section of the Orange Book and had not been withdrawn for reasons of safety or effectiveness. This means the historical brand status should not be used to claim those specific branded tablets are currently sold. It does not automatically invalidate the legal approval pathway for generic tablets referencing the former brand.
The name Flagyl may still appear in educational materials, legacy prescriptions and pharmacy databases. That historical visibility should prompt a product check, not an assumption of branded stock. In particular, 375 mg capsule labeling is a separate product discussion from the discontinued branded tablet presentations.
Metronidazole 250 mg and 500 mg tablets identify ordinary oral tablet strengths. A 375 mg capsule is a different strength and dosage form, and 750 mg extended-release tablets have their own release mechanism. A prescription should explicitly account for those properties. The pharmacy cannot decide that a numerical conversion creates an interchangeable product on the patient's initiative.
The same boundary applies to oral liquids: LIKMEZ has an FDA-approved 500 mg/5 mL suspension label, while an individualized compounded liquid may have different characteristics and does not become an approved generic merely because it contains metronidazole. Review tablet formulations and liquid formulations before making product comparisons.
A dispensing label can identify a generic manufacturer or labeler, the tablet or capsule strength, the quantity and the pharmacy's instructions. National Drug Code information can help distinguish labeled package presentations, but an NDC is not a guarantee that the product is stocked, approved for every indication or interchangeable with another route. Manufacturers and labelers can also differ, which is why the exact package matters.
Color, shape and imprint may vary across approved generic products; appearance by itself cannot establish a medicine's authenticity. If tablets look different from a previous fill, ask the pharmacist to verify the product name, imprint and manufacturer record. Do not assume a visually unfamiliar medicine is counterfeit or, conversely, that a familiar appearance proves legitimacy.
If a prescription names Flagyl while the pharmacy offers metronidazole, first establish which Flagyl strength and dosage form were intended. Then determine whether an approved equivalent is appropriate under state law and the prescriber's directions. An oral tablet should not be substituted with a capsule, suspension, ER tablet or vaginal gel simply because both list metronidazole.
Ask the pharmacist whether the proposed generic matches the reference product and whether any differences in inactive ingredients are relevant to your history. This is a product-matching conversation, not a reason to self-prescribe or modify a course. For readers preparing to fill a prescription, the U.S. buying guide addresses the separate purchase workflow.
The out-of-pocket amount may depend on the generic labeler, package size, pharmacy, insurance terms, quantity and dispensing arrangement. It is not meaningful to compare a single 500 mg tablet price with the price of a prescribed course without specifying the full product and amount. Published discounts and payer rules change; no universal generic price can be inferred from approval status.
A pharmacy may have access to one approved generic presentation but not another, and availability can change. Ask which exact item it can dispense under the prescription and what the final payment terms are. The product availability guide explains how to distinguish product records from actual supply.
FDA therapeutic-equivalence evaluations are tied to particular approved products rather than to all medicines sharing the same active ingredient. A code may help establish that an approved generic and a reference product meet specific equivalence standards within the appropriate dosage form, strength and route. It does not mean that a 375 mg capsule is an authorized generic for a 500 mg tablet or that a dermal formulation can be substituted for a vaginal one.
Brand discontinuation may also affect how reference products appear in a database without erasing approved generic pathways. Pharmacists are trained to interpret these records together with prescription instructions and state substitution requirements. Patients can use the Orange Book to formulate informed questions, but they should not treat an unfamiliar code as permission to choose or switch the product on their own.
Read the prescription for oral route, immediate-release versus ER status, dosage form, strength and prescribed quantity. On the pharmacy label, confirm the same features and identify any generic name, brand reference and manufacturer information. When the offered product differs, have the pharmacy clarify whether it is a permitted equivalent or whether the prescriber must approve a change.
Finally, check relevant medication warnings and ask a professional about any allergies, interacting drugs or concerning symptoms. A properly approved generic does not mean the antibiotic is appropriate for every infection. Use the medicine only under the directions of the clinician who prescribed it.
Generic metronidazole may be FDA-approved as therapeutically equivalent to a particular reference Flagyl product in the same route, dosage form and strength. The brand’s specific marketing status and product identity must still be checked.
They are separate strengths. The pharmacist must follow the prescription and applicable substitution rules; patients should not change the number or strength of tablets without professional instructions.
FDA records list these branded tablets as discontinued and found that they were not withdrawn for reasons of safety or effectiveness. This does not establish current pharmacy availability for any brand or generic.
No. Approved generics can differ in appearance, packaging and some inactive ingredients. The active ingredient, dosage form, strength and route must meet the relevant regulatory standards.
A documented 375 mg product family is oral capsules. Do not infer that a similarly described tablet exists or can substitute for the capsule on a prescription.
No. The extended-release formulation is a distinct product with different release characteristics and label instructions. It should not be substituted for immediate-release tablets by arithmetic.
No. LIKMEZ is an FDA-approved oral suspension; compounded liquids are prepared under different rules and are not automatically FDA-approved generics or interchangeable with it.
Review the pharmacy dispensing label and ask the pharmacist about the labeler, product imprint or NDC. Confirm that the product matches the prescription and an appropriate approved listing.
Costs vary by product, pharmacy, insurance, quantity and payment terms. Generic status does not guarantee a specific price or stock level.
Discuss the question with the pharmacist. Any substitution needs to be permitted and appropriate for the exact prescription, and clinical concerns should be referred to the prescriber.